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We read with interest the comments on our recent paper
[1, 2]. We think that some points should be clarified to your
readers as well as the authors of these comments. Our recent
study showed that at least 435 out of 1072 patients (40.5%) in
our center were intentionally or accidentally intoxicated by
methadone, of whom 216 (20.2%) were younger than 12 years
and were admitted to the pediatric ward [3].
Therefore, we believe that the applicability of this ther-
apeutic approach is quite noticeable. We agree that some
opioid-naive methadone-intoxicated patients may hide their
dependency in history taking but naloxone challenge test
will reveal it soon. Starting administration of 0.05–0.1mg
naloxone to each patient even in those who claim not to be
dependent is recommended. Withdrawal syndrome caused
by oral naltrexone in opioid dependents is usually not life
threatening except in ischemic heart disease patients as our
previous study showed one death among 132 cases (0.8%) [4].
This fatality is different from long withdrawal precipitated
by naltrexone pellet implantation that the authors have
mentioned [1]. By the way, we emphasize naloxone challenge
test in all patients to prevent withdrawal syndrome.
Although we had no morbidity and mortality in naltrex-
one group in hospital and in our follow-up clinic, we agree
that 50mg naltrexonemay not be enough.The reasonwhywe
did not face delayed respiratory depression may be explained
by the period of prehospital admission in which methadone
half-life had partly passed. This theoretical limitation can be
resolved by administration of 150mg naltrexone to increase
its time of effect to 72 hours.Thus, we recommend a naloxone
challenge test, giving 50mg naltrexone if no withdrawal syn-
drome is observed and giving additional 100mg naltrexone if
the first dose is tolerated.
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